FDA is wholeheartedly embracing continuous manufacturing as a move that will lower drug costs and reduce product shortages, but the Association for Accessible Medicines is concerned the move could have unintended negative consequences for generic drug makers. AAM wants the agency to issue guidance stating that generics will not be required to use continuous manufacturing, even when the brands they copy do. AAM's position on continuous manufacturing left multiple experts Inside Health Policy spoke with scratching their heads. Two of...